AMLX

Amylyx Pharmaceuticals Inc

AMLX.US amylyx.com + Research + Basket
CIK 0001658551
Employees 136
Phone 617 682 0917
Fiscal year end December
IPO Jan 07, 2022
Address 55 Cambridge Parkway, Cambridge, MA, United States, 02142
28.05
-0.63 (-2.20%)
USD · NASDAQ
52-week range
10.83
41.14
Trading at 57% of the 52-week range
Market Cap
3.52B
P/E Ratio
0.00
Forward P/E
2.77
Book Value
2.15
Div. Yield
N/A
% Institutions
94.45%
% Insiders
7.16%

1 Year

+106.5%

3 Year

+82.0%

10 Year

+58.7%
Description

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Actions

Add an action for AMLX.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Joshua B. Cohen Co-Founder, Co-CEO & Director 1992
Mr. Justin B. Klee Co-CEO & Director 1991
Mr. James M. Frates M.B.A. Chief Financial Officer 1967
Dr. Camille L. Bedrosian M.D. Chief Medical Officer 1953
Mr. Tom Holmes Chief Technical Operations Officer NA
Ms. Lindsey Allen Head of Investor Relations & Communications NA
Ms. Gina M. Mazzariello J.D. Chief Legal Officer & General Counsel 1972
Ms. Linda A. Arsenault Chief Human Resources Officer NA
Ms. Tammy Sarnelli Global Head of Regulatory Affairs NA
Dr. Machelle Manuel Ph.D. VP & Head of Global Medical Affairs NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Jan 16, 2026 Joshua B Cohen N/A Sale 1.97K $13.83 $27.30K SEC
Jan 16, 2026 Justin B Klee N/A Sale 2.00K $13.89 $27.71K SEC
Jan 15, 2026 Joshua B Cohen N/A Sale 136.19K $13.59 $1.85M SEC
Jan 06, 2026 James M Frates N/A Sale 3.33K $11.11 $36.95K SEC
Jan 06, 2026 Joshua B Cohen N/A Sale 7.72K $11.09 $85.56K SEC
Dec 23, 2025 Karen Firestone N/A Purchase 8.10K $12.45 $100.85K SEC
Dec 01, 2025 Camille L Bedrosian N/A Sale 6.58K $14.35 $94.42K SEC
Sep 30, 2025 Camille L Bedrosian N/A Sale 12.04K $14.58 $175.53K SEC
Sep 30, 2025 Gina Mazzariello N/A Sale 8.83K $14.58 $128.71K SEC
Sep 30, 2025 James M Frates N/A Sale 10.56K $14.65 $154.67K SEC
Sep 30, 2025 Joshua B Cohen N/A Sale 29.93K $14.35 $429.54K SEC
Sep 30, 2025 Justin B Klee N/A Sale 29.98K $14.38 $431.04K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 16.73M Jun 30, 2026 13.33% $0.01 0.59%
BlackRock Inc 8.83M Jun 30, 2026 7.03% $0.00 -0.02%
Perceptive Advisors LLC 8.33M Jun 30, 2026 6.64% $2.25 0.60%
TCG Crossover Management, LLC 6.24M Jun 30, 2026 4.97% $2.70 0.00%
COMMODORE CAPITAL LP 5.65M Jun 30, 2026 4.50% $6.04 0.00%
Jupiter Topco LLC 5.24M Jun 30, 2026 4.17% $0.04 0.00%
HHG PLC 4.99M Mar 31, 2026 3.97% $0.03 11.65%
Saturn V Capital Management LLC 4.62M Jun 30, 2026 3.68% $11.91 6.30%
Vanguard Capital Management, LLC 4.22M Jun 30, 2026 3.37% $0.00 2.00%
Morgan Stanley - Brokerage Accounts 3.13M Jun 30, 2026 2.49% $0.00 43.91%
Driehaus Capital Management LLC 3.04M Jun 30, 2026 2.42% $0.32 1.67%
First Light Asset Management, LLC 3.02M Jun 30, 2026 2.41% $3.30 -5.25%
Franklin Templeton Inc 2.95M Jun 30, 2026 2.35% $0.01 30.45%
The Goldman Sachs Group Inc 2.86M Jun 30, 2026 2.28% $0.00 8.84%
State Street Corp 2.60M Jun 30, 2026 2.07% $0.00 10.16%
Geode Capital Management, LLC 2.34M Jun 30, 2026 1.86% $0.00 5.63%
Adage Capital Partners Gp LLC 1.90M Jun 30, 2026 1.51% $0.05 -46.64%
JPMorgan Chase & Co 1.86M Jun 30, 2026 1.48% $0.00 1,067.24%
683 Capital Management LLC 1.53M Mar 31, 2026 1.22% $1.11 -7.27%
Siren, L.L.C. 1.48M Jun 30, 2026 1.18% $0.54 20.37%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 3.80M 3.03% ▲ 0.32% Sep 30, 2026
2 iShares Russell 2000 ETF 2.69M 2.15% ▼ 0.66% Sep 30, 2026
3 Fidelity Advisor Biotechnology I 2.43M 1.94% ▲ 0.00% Aug 31, 2026
4 Fidelity Small Cap Growth 2.12M 1.69% ▲ 0.00% Jul 31, 2026
5 Franklin Biotechnology Discv A(acc)USD 1.72M 1.37% ▲ 0.00% Sep 30, 2026
6 Fidelity Select Health Care 1.60M 1.27% ▲ 12.68% Aug 31, 2026
7 Fidelity Select Biotechnology 1.47M 1.17% ▲ 33.99% Aug 31, 2026
8 Eventide Healthcare & Life Sciences I 1.32M 1.06% ▼ 12.39% Jun 30, 2026
9 Strategic Advisers Fidelity US TtlStk 1.31M 1.04% ▲ 15.22% Aug 31, 2026
10 Fidelity Stock Selector Small Cap 1.26M 1.00% ▲ 0.01% Jul 31, 2026

Financial Highlights

▼
Market Cap: $3.52B
EBITDA: $-161.73M
Book Value: $2.15
Earnings/Share: $-1.41
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -44.13%
ROE (TTM): -74.73%
Revenue (TTM): $-665.00K
Revenue/Share (TTM): $-0.01
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -99.60%

Valuation Metrics

Enterprise Value: $3.28B
Trailing P/E: 0.00
Forward P/E: 2.77

Shares Statistics

Shares Outstanding: 125.51M
Shares Float: 97.28M
% Insiders: 7.16%
% Institutions: 94.45%
Shares Short: 13.25M
Shares Short (Prior Month): 12.67M
Short Ratio: 9.49
Short % Float: 13.22%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-525.00K
Gross Profit
subtotal
$-525.00K
SG&A
adjust
$-62.89M
R&D
adjust
$-90.40M
Operating Income
subtotal
$-153.29M
Other / Non-Operating Items
adjust
$8.56M
Net Income
subtotal
$-144.74M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AMLX.US!